Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mediator of RNA polymerase II transcription subunit 14 (MED14) is a large scaffolding protein that acts as a crucial architectural and functional backbone of the Mediator complex, an evolutionarily conserved multiprotein complex required for regulated transcription of nearly all RNA polymerase II-dependent genes. MED14 bridges the head, middle, and tail modules of the Mediator, facilitating structural integrity, and is critical for both basal and activator-dependent (e.g., p53) transcription. Its interaction with RNA polymerase II is essential for transcription initiation. MED14 also associates with general transcription factors, nuclear receptors, and certain cofactors including CRSP and thyroid hormone receptor complexes. Mutations or dysregulation of MED14 may have a role in cancer and other disorders of transcription, but it is not a direct therapeutic target, biomarker, or druggable protein as of current knowledge[1][2][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mediator of RNA polymerase II transcription subunit 14 (MED14).